Posts Tagged ‘treatment development’

Drug Development Gets Even More Personal, Precise and Tailored

March 27th, 2012
Posted by

As we’ve discussed, Eric Topol’s “How to Change Medicine” provides valuable insights on how tailoring treatments in the clinic could boost health care effectiveness and lower costs. But we at Popper and Company would like to see industry take an additional step by using the techniques Dr. Topol recommends for patient care to develop drugs more efficiently.
The technology Topol recommends to stratify patients could also streamline drug development. In fact, the FDA is suggesting that faster approvals of antibiotics could result from smaller clinical trials that test antibiotics targeted against drug-resistant bacteria.
We now know enough about molecular biology that we can apply genomics/proteomics/metabolomics to drug development (DNA screening, identifying and validating surrogate markers, or characterizing tumors by genetic makeup). However, tailored treatments can run into challenges, including  heterogeneity in tumor cells as recently described in the New England Journal of Medicine, that resist even targeted biological treatments.
  Read the rest of this entry »

Tags: , , , , , ,
Posted in Our Views | Comments Off on Drug Development Gets Even More Personal, Precise and Tailored